Exec-Edge, Author at ExecEdge - Page 6 of 131

Imviva’s CTA313 Lupus Drug Shows Promising Remission Results

Imviva’s CTA313 Lupus Drug Shows Promising Remission Results

By Daniella Parra Imviva Biotech said data showed its CTA313 drug resulted in 50% of patients going into remission for systemic lupus. Many patients experience incomplete responses, recurrent flares and long-term treatment-related toxicity, it said. “The clinical activity observed with...

a.k.a. Brands Sees Q1 Sales Growth, Raises 2026 Guidance

a.k.a. Brands Sees Q1 Sales Growth, Raises 2026 Guidance

By Karen Roman a.k.a. Brands Holding Corp. (NYSE: AKA) said first quarter net sales rose 3% to $132.5 million compared to $128.7 million the year prior Adjusted EBITDA was $5.1 million, or 3.9% of net sales, compared to $2.7 million,...

Input your search keywords and press Enter.